Arrowstreet Capital Limited Partnership Raises Position in Zoetis Inc. $ZTS

Arrowstreet Capital Limited Partnership grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 83.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,697,827 shares of the company’s stock after acquiring an additional 1,227,085 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.61% of Zoetis worth $394,746,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently made changes to their positions in ZTS. Vanguard Group Inc. grew its position in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares during the period. Geode Capital Management LLC boosted its stake in Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the last quarter. Norges Bank bought a new position in Zoetis during the second quarter valued at $809,491,000. Brown Advisory Inc. grew its stake in shares of Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after acquiring an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 3.8%

ZTS opened at $115.25 on Friday. Zoetis Inc. has a 12 month low of $115.23 and a 12 month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The business’s 50-day moving average price is $125.54 and its 200-day moving average price is $132.19. The company has a market cap of $48.65 billion, a P/E ratio of 19.14, a P/E/G ratio of 1.83 and a beta of 0.95.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company earned $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZTS. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday. Stifel Nicolaus reduced their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Finally, UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.